Google AI Tool Identifies a Tumor’s Mutations From an Image

Google AI Tool Identifies a Tumor’s Mutations From an Image

  • September 17, 2018
Table of Contents

Google AI Tool Identifies a Tumor’s Mutations From an Image

The algorithm can distinguish between different kinds of lung cancer, and could speed up a patient’s diagnosis by weeks. The image shows the process by which an AI tool analyzes a slice of cancerous tissue to create a map that tells apart two lung cancer types which require different treatments, with squamous cell carcinoma in red, lung squamous cell carcinoma in blue, and normal lung tissue in gray. For decades, doctors have relied on the well-trained eyes of human pathologists to give their patients a cancer diagnosis.

Now, researchers are teaching machines to do that time-intensive work in as little as a few seconds. In new research published today in Nature Medicine, scientists at New York University re-trained an off-the-shelf Google deep learning algorithm to distinguish between two of the most common types of lung cancers with 97 percent accuracy. This type of AI—the same tech that identifies faces, animals, and objects in pictures uploaded to Google’s online services—has proven adept at diagnosing disease before, including diabetic blindness and heart conditions.

But NYU’s neural network learned how to do something no pathologist has ever done: identify the genetic mutations teeming inside each tumor from just a picture.

Source: wired.com

Share :
comments powered by Disqus

Related Posts

New anti-cancer drugs put cancers to sleep—permanently

New anti-cancer drugs put cancers to sleep—permanently

In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer therapies. Published today in the journal Nature, the research reveals the first class of anti-cancer drugs that work by putting the cancer cell to sleep – arresting tumour growth and spread without damaging the cells’ DNA. The new class of drugs could provide an exciting alternative for people with cancer, and has already shown great promise in halting cancer progression in models of blood and liver cancers, as well as in delaying cancer relapse.

Read More
AI System Approved For Diabetic Retinopathy Diagnosis

AI System Approved For Diabetic Retinopathy Diagnosis

A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy. The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.

Read More
Researchers Identify Molecule With Anti-Aging Effects On Vascular System

Researchers Identify Molecule With Anti-Aging Effects On Vascular System

A molecule produced during fasting or calorie restriction has anti-aging effects on the vascular system, which could reduce the occurrence and severity of human diseases related to blood vessels, such as cardiovascular disease, according to a study led by Georgia State University. In this study, the research team explores the link between calorie restriction (eating less or fasting) and delaying aging, which is unknown and has been poorly studied. The findings are published in the journal Molecular Cell.

Read More